Oxidized LDL induces in vitro lymphocyte activation in antiphospholipid syndrome

References

• de Groot PG, Derksen RH. Antiphospholipid antibodies: Update on detection, pathophysiology, and treatment. Curr Opin Hematol. 2004; 11:165–169.
   PubMed Web of Science ®Google Scholar
• Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: A systematic review. JAMA. 2006; 259:1050–1057.
   Google Scholar
• Cabral AR, Amigo MC, Cabiedes J, Alarcon-Segovia D. The antiphospholipid/cofactor syndromes: A primary variant with antibodies to B2-glycoprotein-I but no antibodies detectable in standard antiphospholipid assays. Am J Med. 1996; 101:472–481.
   PubMed Web of Science ®Google Scholar
• Yoshida K, Arai T, Kaburaki J, Ikeda Y, Kawakami Y, Kuwana M. Restricted T-cell receptor beta-chain usage by T cells autoreactive to β2-glycoprotein I in patients with antiphospholipid syndrome. Blood. 2002; 99:2499–2504.
   Google Scholar
• Kuwana M, Matsuura E, Kobayashi K, Okazaki Y, Kaburaki J, Ikeda Y, Kawakami Y. Binding of β2-glycoprotein I to anionic phospholipids facilitates processing and presentation of a cryptic epitope that activates pathogenic autoreactive T cells. Blood. 2005; 105:1552–1557.
   PubMed Web of Science ®Google Scholar
• Yamaguchi Y, Seta N, Kaburaki J, Kobayashi K, Matsuura E, Kuwana M. Excessive exposure to anionic surfaces maintains autoantibody response to β2-glycoprotein I in patients with antiphospholipid syndrome. Blood. 2007; 110:4312–4318.
   PubMed Web of Science ®Google Scholar
• Libby P. Inflammation in atherosclerosis. Nature. 2002; 420:868–874.
   PubMed Web of Science ®Google Scholar
• Stone PH. Evaluating cardiovascular pathophysiology and anatomy in atherosclerosis. Am Heart Hosp J. 2005; 3:187–192.
   Google Scholar
• Asatryan L, Ziouzenkova O, Duncan R, Sevanian A. Heme and lipid peroxides in hemoglobin-modified low-density lipoprotein mediate cell survival and adaptation to oxidative stress. Blood. 2003; 102:1732–1739.
   PubMed Web of Science ®Google Scholar
• Jeney V, Komódi E, Nagy E, Zarjou A, Vercellotti GM, Eaton JW, Balla G, Balla J. Supression of hemin-mediated oxidation of low-density lipoprotein and subsequent endothelial reactions by hydrogen sulfide (H(2)S). Free Radic Biol Med. 2009; 46:616–623.
   PubMed Web of Science ®Google Scholar
• Boullier A, Bird DA, Chang MK, Dennis EA, Friedman P, Gillotre-Taylor K, Hörkkö S, Palinski W, Quehenberger O, Shaw P, Steinberg D, Terpstra V, Witztum JL. Scavenger receptors, oxidized LDL, and atherosclerosis. Ann NY Acad Sci. 2001; 947:214–222.
   PubMed Web of Science ®Google Scholar
• Leitinger N. Oxidized phospholipids as triggers of inflammation in atherosclerosis. Mol Nutr Food Res. 2005; 49:1063–1071.
   PubMed Web of Science ®Google Scholar
• Witztum JL, Berliner JA. Oxidized phospholipids and isoprostanes in atherosclerosis. Curr Opin Lipidol. 1998; 9:441–448.
   PubMed Web of Science ®Google Scholar
• Soltesz P, Veres K, Laczik R, Der H, Csipo I, Timar O, Szomjak E, Szegedi G, Szodoray P. Evaluation of antibodies to oxidized low-density lipoprotein and assessment of C-reactive protein in acute coronary syndrome and stable coronary artery disease. Thromb Haemost. 2007; 98:413–419.
   PubMed Web of Science ®Google Scholar
• Kajiwara T, Yasuda T, Matsuura E. Intracellular trafficking of beta2-glycoprotein I complexes with lipid vesicles in macrophages: Implications on the development of antiphospholipid syndrome. J Autoimmun. 2007; 29:164–173.
   PubMed Web of Science ®Google Scholar
• Lopez D, Kobayashi K, Merrill JT, Matsuura E, Lopez LR. IgG autoantibodies against beta2-glycoprotein I complexed with a lipid ligand derived from oxidized low-density lipoprotein are associated with arterial thrombosis in antiphospholipid syndrome. Clin Dev Immunol. 2003; 10:203–211.
   Google Scholar
• Ames PR, Delgado Alves J, Lopez LR, Gentile F, Margarita A, Pizzella L, Batuca J, Scenna G, Brancaccio V, Matsuura E. Antibodies against beta2-glycoprotein I complexed with an oxidised lipoprotein relate to intima thickening of carotid arteries in primary antiphospholipid syndrome. Clin Dev Immunol. 2006; 13:1–9.
   PubMedGoogle Scholar
• Evans SM, Brittenden J, Adam DJ, Ludlam C, Bradbury AW. Vascular surgical society of Great Britain and Ireland: Prevalence and significance of thrombophilia in patients with intermittent claudication. Br J Surg. 1999; 86:702–703.
   Google Scholar
• Spronk PE, Overbosch EH, Scut NH. Severe atherosclerotic changes including aortic occlusion, associated with hyperhomocysteinaemia and antiphospholipid antibodies. Ann Rheum Dis. 2001; 60:699–701.
   PubMedGoogle Scholar
• Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, Derksen RH, De Groot PG, Koike T, Meroni PL, Reber G, Shoenfeld Y, Tincani A, Vlachoyiannopoulos PG, Krilis SA. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4:295–306.
   PubMed Web of Science ®Google Scholar
• Karakantza M, Theodorou GL, Meimaris N, Mouzaki A, John E, Andonopoulos AP, Maniatis A. Type 1 and type 2 cytokine-producing CD4+ and CD8+T cells in primary antiphospholipid syndrome. Ann Hematol. 2004; 83:704–711.
   PubMed Web of Science ®Google Scholar
• Itabe H, Yamamoto H, Imanaka T, Shimamura K, Uchiyama H, Kimura J, Sanaka T, Hata Y, Takano T. Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res. 1996; 37:45–53.
   PubMed Web of Science ®Google Scholar
• Xavier HT, Abdalla DS, Martinez TL, Ramires JA, Gagliardi AR. Effects of oxidized LDL on in vitro proliferation and spontaneous motility of human coronary artery endothelial cells. Arq Bras Cardiol. 2004; 83:493–497.
   Google Scholar